Behçet’s disease

Showing 3 posts of 3 posts found.

celgene_building

Celgene’s Otezla becomes first and only FDA-approved therapy for oral ulcers in Behçet’s Disease

July 22, 2019
Sales and Marketing Behçet's disease, Behçet’s Disease, Celgene, apremilast, otezla, pharma

Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …

Living with Behçet’s disease

July 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Behçet's disease, patient experience, pharma

Suzanne Morris speaks to Pharmafocus to discuss her life with Behçet’s disease, a rare condition characterised by the inflammation of …

celgene_1_02

Celgene reveals strong P3 Otezla data in rare inflammatory condition

February 19, 2018
Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma

Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …

Latest content